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Objectives: Body composition alterations occur during aging. The purpose of the present analysis was to
explore the functional consequences of the overlap of sarcopenia and osteoporosis, and the potential role
of insulin-like growth factor 1 (IGF1) in their development in the oldest old.
Setting and Participants: Eighty-seven nonagenarians from the Louisiana Healthy Aging Study were
included.
Measures: The definition of sarcopenia was based on appendicular lean mass (ALM). Osteoporosis was
diagnosed based on bone mineral density (BMD) T score. Four phenotypes were compared: (1) healthy
body composition, that is, nonosteoporotic nonsarcopenic (CO, control group), (2) osteoporotic (O, low
BMD T score), (3) sarcopenic (S, low ALM), and (4) osteosarcopenic (OS, low BMD T score and low ALM).
Sex- and age-specific IGF1eStandard Deviation Scores (SDS) were calculated. The Continuous Scalee
Physical Functional Performance (CS-PFP) test was performed.
Results: In OS men, IGF1-SDS values (0.61 0.37 vs 0.04  0.52, P ¼ .02) were lower than those in CO
males (control group), whereas IGF1-SDS were similar in the 4 body composition phenotypes in
women. In men only, ALM was positively associated with IGF1-SDS values (P ¼ .01) independent of
age and C-reactive protein concentration. Regarding bone health, we found no association between
IGF1-SDS values and BMD. IGF1-SDS was not associated with functional performance (CS-PFP) in men
and women.
Conclusions/Implications: IGF1 sensitivity in skeletal muscle and bone may differ by sex in the oldest old.
IGF1 status did not appear to affect physical functionality. Determinants and clinical and functional
characteristics of osteosarcopenia need to be further investigated in order to define conclusive diagnostic
criteria.
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te and Long-Term Care Medicine.The aging process is characterized by deleterious alterations in
body composition including declines in lean body mass (LBM; sarco-
penia) and bone mineral density (BMD; osteopenia and osteoporosis)
with a concomitant increase in relative body fat.1,2 Because bone
health has been shown to be involved in a complex interplay between
skeletal muscle and adipose tissue, the term “osteosarcopenic obesity”
has been coined1 to indicate the concurrence of high body fat, low
LBM, and low BMD. Currently, however, a universally accepted defi-
nition of sarcopenia is lacking, leading to a difficult and quite variable
diagnostic.3 Both hormonal status and systemic inflammation have
E. Poggiogalle et al. / JAMDA xxx (2018) 1e62been postulated to play a pivotal role in the age-related impaired body
composition.1,4
Among endocrine contributors, a low somatotropic axis activity
(also called somatopause) is recognized as a trigger of age-related
disturbances in body composition and is now suggested as a target
for anti-aging treatment.5 However, results from randomized clinical
trials with administration of recombinant growth hormone (GH) have
not been conclusive about its beneficial impact on body composition
and physical functionality and some trials have been associated with
significant adverse side effects.6 Cross-sectional studies showed a
positive association between plasma insulin-like growth factor 1
(IGF1) concentration and healthier body composition.4,5 However, the
combination of the newly described body composition phenotypes
with functional status and endocrine health have not been explored in
the oldest old population. The aims of the present study were there-
fore to assess the prevalence of body composition phenotypes (sar-
copenia, osteoporosis, and their overlaps) in nonagenarians, and
to examine their relationships with IGF1 status and physical
functionality.
Methods
Study Participants
The Louisiana Healthy Aging Study (LHAS) has been previously
described.7,8 Participants aged >89 years living within the Greater
Baton Rouge Area, were recruited as a community representative
cohort. A total of 275 nonagenarians were enrolled in the LHAS, of
whom 103 were included in a substudy and underwent a thorough
assessment of metabolic and endocrine health, according to criteria
described elsewhere.7,8 Data from87 subjects (37men and 50women)
out of 103 nonagenarians were included in this analysis. Altogether, 16
participants were excluded because of the use of medications poten-
tially affecting body composition (ie, corticosteroids for systemic use,
hormone replacement therapy and insulin administration) or clinical
conditions making them unable to accomplish the required testing.
The study was approved by the Institutional Review Board of the
Pennington Biomedical Research Center and the LSU Health Science
Center. Written informed consent was provided by all participants.
Anthropometrics
Body weight was measured to the nearest 0.1 kg with an elec-
tronic scale (Detecto, Webb City, MO), and height wasmeasured to the
nearest 0.5 cm with a stadiometer (Holtain; Crymych, Dyfed, UK).
Body mass index (BMI) was calculated as weight divided by height
squared (kg/m2). Underweight was defined as BMI 18.5, normal
weight as BMI>18.5 and < 25, overweight as BMI 25 but <30, and
obesity as BMI 30.
Body Composition
LBM, body fat, and BMD were measured by dual energy x-ray ab-
sorptiometry (DXA) on a QDA 4500A instrument (Hologic, Bedford,
MA). Appendicular lean mass (ALM) was obtained as the sum of lean
mass of arms and legs. Osteopenia and osteoporosis were diagnosed
when BMD T score was 1.0 or 2.5, respectively, for at least at one of
the following segments of the skeleton: femoral neck or lumbar
spine.1,9e11 Because of the lack of standardization criteria, several
indices of sarcopenia (eg, appendicular skeletal muscle mass index,
here indicated as ALM/height2, ALM/BMI, ALM/weight, and ALM as
absolute value; Supplemental Table 1) were first used to evaluate the
prevalence of sarcopenia and its overlap with osteoporosis and/or
obesity. The 4 cutpoints for sarcopenia were as follows: ALM/height2
of 7.26 in men or 5.45 in women12; ALM/weight (percentage) of<25.72% in men or <19.43% in women13; ALM/BMI of <0.789 in men
or <0.512 in women14; ALM (kilograms) of <19.75 kg in men or
<15.02 kg in women14; ALM (kilograms) adjusted for height (meters)
and fat mass (kilograms) of <20th percentile of the distribution of
residuals.15
Because the prevalence of sarcopenia based on different defini-
tions was highly variable, and the vast majority of participants were at
least osteopenic, we used a modified approach as in Drey et al,16
relying on the sex-specific median values of ALM and BMD T score
(at either femoral neck or lumbar spine, or both) to divide participants
into 4 body composition phenotypes: (1) nonosteo-nonsarcopenic
phenotype, without osteoporosis or sarcopenia (controls: high ALM
and high BMD T score), (2) osteoporosis only (low BMD T score and
high ALM), (3) sarcopenia only (low ALM and high BMD T score), and
(4) osteosarcopenia (low ALM and low BMD T scores).
Physical Activity
Total daily energy expenditure and resting metabolic rate (RMR)
were measured as previously described.8 The level of physical activity
(PAL) was calculated as previously described: TEE/(RMR þ 0.1*TEE).8
Physical Functionality
The short version of the Continuous ScaleePhysical Functional
Performance (CS-PFP-10) test was used to assess physical functional
capacity. CS-PFP-10 consists of 10 tasks examining 5 domains: upper-
body strength, upper-body flexibility, lower-body strength, balance/
coordination, and endurance. Scores range from 0 to 100, with higher
scores mirroring higher functional ability.7,17 A score of 57 has been
considered as the threshold of physical independence.18
Frailty, Biological Age, and Polypharmacy
The Frailty Index “FI34,” including 34 health variables, was used as
a measure of frailty and biological age.19 According to the medical
history andmedication counting, polypharmacywas defined in case of
use of 5 medications.20
IGF1, Albumin, and C-Reactive Protein Assays
Blood samples were drawn after an overnight fast. Serum con-
centrations of IGF1 were determined using enzyme-linked immuno-
sorbent assay (Diagnostic System Laboratories, Webster, TX). Given
that IGF1 concentrations are related to age or sex, we calculated the
standard deviation score (SDS) of IGF1 according to age and sex.21 The
SDS of IGF1 levels were calculated as follows: SDS ¼ (measurement e
mean)/SD. Means and SDs of IGF1 levels were obtained from NHANES
III participants aged 89 years (26 women and 14 men). No partici-
pant, among our nonagenarians, had an IGF1-SDS value below 2, a
threshold considered as IGF1 deficiency. Serum albumin levels were
measured by a timed endpoint method, on a Synchron CX7 (Beckman
Coulter, Brea, CA). C-reactive protein (CRP) levels were measured by
immunoassays on a DPC 2000 (Diagnostic Product Corporation, Los
Angeles, CA). The CRP/albumin ratio was calculated.22
Statistical Analysis
Data are presented as means  SD. Data analyses were performed
using IBM SPSS Statistics, version 23 (IBM Corp, Armonk, NY). Distri-
butions of continuous variables were examined for skewness and
kurtosis, and were logarithmically transformed when appropriate.
Log-transformed variables are presented as untransformed values for
ease of reading. Chi-square test, 1-way analysis of variance, and
analysis of covariance with post hoc multiple comparisons with
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examine the relationship between variables, and multiple linear
regression analysis was performed to investigate the independent
association of the response variable with the selected explanatory
variable. Log-ALM and log-L1-L4-BMD were used as dependent vari-
ables in multiple regression analyses. The covariates included in the
models were chosen a priori among those factors expected to influ-
ence the dependent variable, based on biological mechanisms or ev-
idence from research; they are specified in the Results section. The
level of significance for all statistical tests was set at P < .05.
Results
Study Participants
Eighty seven nonagenarians were included in the present analysis
(37 men and 50 women; age: 92  2 years, BMI: 24.8  3.9). Partici-
pants’ medical history, use of medications, and metabolic health are
described in Supplemental Table 2. Polypharmacy was observed in
42.5% of participants.
Body Composition
Supplemental Figure 1 presents the prevalence rates of BMI cate-
gories (panel A), of osteopenia and osteoporosis for femoral neck and
lumbar spine (panel B), and of sarcopenia according to different
criteria (panel C). Overall, 2.3% of study participants were under-
weight (women only), 8% were obese, whereas the majority had
normal weight (50.6%) or overweight (39.1%) BMIs. Osteoporosis in
any segment (femoral neck or lumbar spine) was present in 48% of the
study population (64% of women and in 27% of men). The prevalence
of sarcopenia ranged from 1.2%, when using the accepted cutoff values
for the index of ALM divided by weight (ALM/weight; %) to 34.5%
according to the ALM alone (kg).
Body Composition Phenotypes
To overcome thehighly variable prevalence of sarcopenia according
to different published criteria, we classified study participants in 4
phenotypes based on median ALM and median BMD T scores, as
described in theMethods section and in linewith the approach byDreyTable 1
Demographics, Anthropometrics, and Body Composition
Nonosteoporotic-Nonsarcopenic
Control Group (CO), n ¼ 14
Sarcopenic Grou
n ¼ 16
M/F, n 6/8 7/9
W/AA/Other, n 12/1/1 12/0/4
Age, y* 92  2 91  1
Weight, kg 74.7  10.4 61.4  9.2 ay
Height, m* 1.65  0.08 1.62 0.08
BMI* 27.3  3.2 23.2  2.7 bz
Body fat, % 34  5 33  7
FM, kg 25.1  5.2 19.9  5.5
LBM, kg* 49.3  2.1 41.0  2.0 az
ALM, kg* 20.9  4.2 16.7  3.2 az
ALM/height2, kg/m2* 7.6  1.0 6.4  0.8 ay
ALM/BMI* 0.76  0.14 0.72  0.13
(ALM/weight)  100 28  3 27  3
L1-L4 BMD, g/cm2* 1.15  0.13 1.23  0.22
Femoral neck BMD, g/cm2 0.65  0.07 0.71  0.11
AA, African American; F, females; FM, fat mass; L1-L4, lumbar spine; M, males; Other, o
Boldface indicates significance.
*Log-transformed variables; a: CO vs S; b: CO vs O; c: CO vs OS; d: O vs S; e: O vs OS
yP < .01.
zP < .05.
xAdjustment for CRP levels.et al16 (Table 1): 16% of the participants were nonosteoporotic and
nonsarcopenic (COfor controls), 35%hadonlyosteoporosis (O), and18%
had only sarcopenia (S), whereas the remaining 31% had both osteo-
porosis and sarcopenia (OS). Demographics, anthropometrics,
adiposity, LBM, andBMD indifferent bodycompositionphenotypes are
described in Table 1. Age was not different in the 4 body composition
phenotypic groups. BMI was significantly lower in sarcopenic and
osteosarcopenic groups when compared to subjects with normal body
composition (CO). Furthermore, subjects with osteosarcopenia had a
lower BMI than osteoporotic individuals (P< .05). Body fat percentage
was not different across the 4 body composition phenotypes, whereas
fat mass in absolute value was significantly lower in OS older adults
than in the group with normal body composition (P < .05). By defini-
tion, LBM and ALM were significantly lower in both sarcopenic and
osteosarcopenic subjects compared to individuals with normal body
composition or with osteoporosis (P < .01). Similarly, BMD at the
lumbar spine and at the femoral neck was significantly lower in the
group with both osteoporosis and sarcopenia (OS) when compared to
the nonosteo-nonsarcopenic and sarcopenic groups (P < .01). No dif-
ferences were observed between groups regarding the prevalence of
smoking, alcohol intake, or use of osteoporosis medications.
Multiple regression analysis did not reveal any significant associ-
ation between log-ALM and femoral neck BMD (P ¼ .93) or lumbar
spine BMD (P ¼ .16) with or without adjustment for age, sex, CRP
levels, body fat (percentage), smoking status, alcohol intake, and use
of osteoporosis medications. Similarly, when stratified by sex, no
significant association was observed between log-ALM and femoral
neck or lumbar spine BMD adjusting the models for age, body fat
percentage, and CRP levels in either males or in females.
Body Composition Phenotypes and IGF1
IGF1 levels and IGF1-SDS values were compared in the 4 body
composition phenotypes according to sex (males: CO, n ¼ 6; S, n ¼ 7;
O, n ¼ 13; OS, n ¼ 11; and females: CO, n ¼ 8; S, n ¼ 9; O, n ¼ 17; OS,
n ¼ 16).
Men with both osteoporosis and sarcopenia (OS) were older than
menwith only sarcopenia (94  3 vs 91 1 years, P ¼ .02) and tended
to be older than osteoporotic men (94  3 vs 92  1 years, P ¼ .06).
Neither body fat percentage nor fat mass were different between
groups in men. In OS men, log-IGF1 concentrations (non-log-p (S), Osteoporotic Group (O),
n ¼ 30
Osteosarcopenic Group (OS),
n ¼ 27
P
13/17 11/16 .99
27/1/2 25/0/2 .32
92  2 93  2 .12
69.6  11.5 dy 58.6  11.3 cy, ey <.001
1.64  0.09 1.58  0.09 .06
26.0  4.5 23.1  3.1 cy, ez .001
31  8 31  7 .66x
21.8  8.2 18.3  6.1 cz .02x
47.5  1.5 dz 39.9  1.5 cy, ey <.001x
20.5  3.9 dy 16.5  3.6 cy, ey <.001x
7.6  1.1 dy 6.5  0.9 cy, ey <.001x
0.80  0.17 0.71  0.15 .14x
30  4 29  4 .27x
0.87  0.12 by, dy 0.90  0.19 cy, fy <.001x
0.56  0.09 bz, dy 0.52  0.09 cy, fy <.001x
ther ethnicities; W, white.
; f: S vs OS.
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(0.61  37 vs 0.04  0.52, P ¼ .02) were significantly lower than in
men with normal body composition (CO) after adjustment for age
(Figure 1). There was, however, no difference in log-IGF1 levels
(P¼ .36) or IGF1-SDS values (P¼ .52) between the 4 body composition
phenotypes in women (Figure 1).
ALM, BMD, and IGF1
A positive correlation was observed between log-ALM and IGF1-
SDS values in men (r ¼ 0.45, P ¼ .005) but not in women (r ¼ 0.22,
P ¼ .13). We performed multiple linear regression analyses to inves-
tigate the independent association of ALM with IGF1-SDS values. In-
dependent of age and CRP concentrations, log-ALM was positively
associated with IGF1-SDS values in men (beta: 0.11, SE: 0.04, P ¼ .01),
even after adjusting for body fat (percentage) (P ¼ .01) or for PAL
(P ¼ .02), confirming the positive association between ALM and IGF1-
SDS (Figure 2). BMD at the femoral neck or lumbar spine was not
associated with IGF1-SDS values with or without adjustment for age,
CRP levels, percentage body fat and smoking status either in men or in
women.
Physical Functionality, PAL, and IGF1
Data from the CS-PFP test were available in a subset of 72 partic-
ipants. Except for 2men and 1 woman, all participants were below the
threshold of physical reserve corresponding to a score equal to 57 at
the CS-PFP test. There was no difference in PAL or functionality scores
among the 4 different body composition phenotypes (Supplemental
Table 3). Furthermore, no significant correlation was observed be-
tween the CS-PFP score and IGF1-SDS values or between PAL and
IGF1-SDS values by sex (data not shown).
ALM and Physical Functionality
Despite the lack of difference in PAL and physical functionality
between the 4 body composition groups, bymultiple linear regression
analyses the CS-PFP score was positively associated with ALM (beta:
2.06, SE: 0.91, P ¼ .03) in men, but not in women, after adjustment for
age and the frailty index (FI34 score).
Body Composition Phenotypes and Inflammation
After adjustment for body fat, CRP levels and CRP/albumin ratio
were higher in sarcopenic individuals compared with theirFig. 1. IGF1-SDS values in men (A) and women (B) in different body composition phenotyp
osteoporotic group; OS, osteosarcopenic group. *OS vs CO: P ¼ .02.osteoporotic counterparts (P < .05). No correlation emerged between
inflammatory biomarkers and IGF1-SDS (data not shown).Discussion
In our community-based cohort of nonagenarians, men with
osteosarcopenia, but not women, exhibited lower IGF1-SDS values
than the control (CO) group; moreover, increased IGF1-SDS values
were associated with larger ALM in men only. Conversely, the coex-
istence of sarcopenia and osteoporosis in a unique phenotype named
osteosarcopenia did not result in a more deleterious impact on func-
tional status than each clinical condition considered separately.
Finally, body composition in men, but not IGF1 status, were related to
physical functionality.
BMD and ALM were not associated in our study population, even
when taking into account the potential interference of body fat in that
association, suggesting that the presence of reduced lean mass was
not detrimental to bone health. Our observations appear to be in
disagreement with findings from Drey et al,16 showing increased bone
turnover markers in older adults aged 65-94 years with osteosarco-
penia compared to controls. Our findings also seem to contradict the
“bone-muscle unit” model,23 suggesting that the crosstalk between
bone and skeletal musclemay be impaired in late life. In a recent study
by Di Monaco et al,24 the association between sarcopenia and osteo-
porosis largely varied depending on the definition and index adopted
to describe low LBM. The variability of the different indices of sarco-
penia to capture concomitant disproportions in body compartments
between groups needs to be further tested in larger cohorts.3
The positive association between ALM and IGF1-SDS values was
present in men only, whereas no association between BMD and IGF1-
SDS was found in men or women. Our findings are consistent with
many studies showing the role of IGF1 as a major mediator of growth
hormone action in protein metabolism in skeletal muscle.4,5 IGF1 acts
as a key upstream regulator of the mammalian target of rapamycin
(mTOR), a serine/threonine kinase playing a pivotal role in the
anabolic signaling in skeletal muscle by25 promoting muscle cell
growth (hypertrophy) and inhibiting apoptosis.26 Gender differences
have been reported in the response to GH replacement therapy in
adults with GH deficiency.27 In fact, short-term as well as long-term
studies provide evidence of a reduced IGF1 responsivity in GH-
deficient women compared to men when treated with rhGH.
Indeed, body composition changes in response to rhGH therapy (ie,
increase in LBM and reduction in adiposity) were more pronounced in
men, indicating a relative GH resistance in women.27e29 Larger size
studies are needed to confirm a potential sexual dimorphism on thees. CO (control group), nonosteoporotic nonsarcopenic group; S, sarcopenic group; O,
Fig. 2. Relationship between ALM and IGF1-SDS in men (A; n ¼ 37) and in women (B; n ¼ 50).
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pattern in the oldest old.
The lack of association between BMD and IGF1 in our study is in
agreement with several studies showing no association between BMD
and IGF1 levels in either sex.30,31 In addition, in older men and post-
menopausal women, GH replacement therapy resulted in discordant
or nonsignificant improvement in BMD.32,33 One can hypothesize that
at the extreme end of the age span, skeletal muscle and bone could
respond differently to the anabolic stimuli of IGF1.
Nonagenarians with different body composition phenotypes had
similar CS-PFP test scores, and osteosarcopenic subjects did not
exhibit a poorer functional status than subjects with sarcopenia or
osteoporosis alone. The lack of differences in PAL among groups may
suggest a floor effect in the oldest old. Notably, in 97% of study par-
ticipants, CS-PFP test scores were below the 57, a threshold usually
predicting older adults with functional limitations.18
Data concerning functional ability and physical performance from
studies based on rhGH therapy are conflicting.34,35 Despite some
studies demonstrating beneficial effects on muscle performance
potentially mediated by IGF1,34 short-term GH administration in
healthy adult and older subjects failed to improve skeletal muscle
contractility or physical performance,34,36 even after an increase in
LBM.37 Our findings of no association between CS-PFP score and IGF1
appear to be in linewith this body of evidence; however, they disagree
with other studies.35
In our study cohort, ALM was a determinant of the physical func-
tionality scores obtained by the CS-PFP test in men, but not inwomen.
Our results suggest that age-related changes in body composition only
are not sufficient to thoroughly characterize the physical functional
status, underlying the need of a multidimensional evaluation in the
oldest old.
The major strength of the present study is the investigation of
determinants of body composition and physical functionality in a
unique community-based cohort of exceptional survivors. However,
some limitations need to be acknowledged: because of the low
prevalence of obesity in our cohort, we were unable to evaluate
thoroughly the relationship between body compartments in the
complex phenotype of osteosarcopenic obesity because BMI may not
be accurate for diagnosing obesity in older adults38; the small sample
size in group comparisons may affect the generalizability of findings;
and finally, the observational nature of our study prevents us from
disentangling the potential causative relationship between the GH/
IGF1 status and the evaluated outcomes.Conclusions/Relevance
Our findings support the potential role of IGF1 action in the
maintenance of skeletal muscle, but not bone mass, in nonagenarians,though gender differences in the relationship between body com-
partments and IGF1 status deserve to be investigated in the oldest old.
We can assume that the 2 tissues may have a differential responsivity
to IGF1 in late life, in contrast with evidence from younger cohorts.
Determinants of the phenotype of osteosarcopenia need to be further
explored in late life, and clear-cut diagnostic criteria await to be
defined conclusively.Supplementary Data
Supplementary data related to this article can be found at https://
doi.org/10.1016/j.jamda.2018.07.007.References
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Supplemental Table 1
Indices of Sarcopenia
Indices of Sarcopenia Authors Approaches Cutpoints
ASM/h2 Baumgartner et al, Rosetta study 2 SD below the mean of a young
reference population (gender- specific)
7.26 kg/m2 in men or 5.45 kg/m2 in women
(ASM/weight)  100 Levine et al, NHANES 2 SD below the mean of a young
reference population (gender-specific)
<25.72% in men or <19.43% in women
ALM/BMI Cawthon et al, FNIH project Clinically significant weakness or slowness
(CART model; gender-specific)
<0.789 in men or <0.512 in women
ALM (kg) Cawthon et al, FNIH project Clinically significant weakness or slowness
(CART model; gender-specific)
<19.75 kg in men or <15.02 kg in women
ALM (kg) adjusted for
height and fat mass
Newman et al, Health ABC study <20th percentile of the distribution of the
residuals (gender-specific)
<20th percentile of the distribution of residuals
ASM, Appendicular Skeletal Muscle Mass; CART, classification and regression trees; FNIH, Foundation for the National Institutes of Health; NHANES, National Health and
Nutrition Examination Survey.
ASM and ALM are used as synonyms, according to the nomenclature chosen by the authors.
Appendix
Supplemental Table 2
Medical History and Use of Medications Potentially Affecting Metabolic Health and
Body Composition
Men, n ¼ 37 Women,
n ¼ 50
All,
n ¼ 87
Ethnicity: W/AA/Other (n) 29/1/7 47/1/2 76/2/9
Age, y, mean  SD 92  2 92  2 92  2
History of cancer 21.6 22.0 21.8
Metabolic syndrome 32.4 50.0 42.5
Major CV events* 21.6 28.0 25.3
Congestive heart failure 13.5 6.0 9.2
Peripheral vascular disease 2.7 6.0 4.0
Rheumatoid arthritis 3.0 11.1 7.3
Kidney disease 10.8 8.0 9.2
Smoking status: never/former/current 40.5/56.8/2.7 70/30/0 57.5/41.4/1.1
Alcohol use: never/former/current 13.5/32.4/54.1 44/8/48 31/18.4/50.6
Use of hypolipidemic agents 18.9 24.0 21.8
Use of antihypertensive agents 75.7 80.0 78.2
Use of antiaggregant/anticoagulant
agents
59.5 66.0 63.2
Use of osteoporosis medications 2.7 28.0 17.2
Polypharmacy (5 medications) 40.5 44.0 42.5
AA, African American; CV, cardiovascular; Other, other ethnicities; SD, standard
deviation; W, white.
Values are percentages unless otherwise noted.
*Myocardial infarction, stroke, or transient ischemic attack.
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Supplemental Table 3
IGF1 Status, Inflammation, Physical Functionality, and Frailty
Variables Nonsarcopenic Nonosteoporotic
Control Group (CO), n ¼ 14
Sarcopenic
Group (S),
n ¼ 16
Osteoporotic
Group (O),
n ¼ 30
Osteosarcopenic
Group (OS),
n ¼ 27
P
IGF1 status IGF1,* mg/L 163  75 130  56 153  67 119  65 .06
IGF1-SDS 0.23  0.79 0.48  0.89 0.17  0.99 0.60  0.92 .31
Inflammation CRP,* mg/L 0.48  0.95 0.71  0.60 yd 0.42  0.75 0.70  1.88 .03z
CRP/albumin* 0.13  0.25 0.19  0.16 yd 0.11  0.20 0.21  0.63 .04z
Protein status Albumin, g/dL 3.8  0.2 3.9  0.3 3.8  0.3 3.8  0.4 .76
Physical activity PAL, n ¼ 81 1.43  0.09 1.41  0.16 1.39  0.25 1.37  0.20 .72
Physical functionality CS-PFP score, n ¼ 72 24  11 29  16 32  18 23  16 .24
Frailty index FI34 score 0.21  0.04 0.19  0.07 0.19  0.07 0.22  0.08 .30
*Log-transformed variables. a: CO vs S; b: CO vs O; c: CO vs OS; d:O vs S; e: O vs OS; f: S vs OS.
yP < .05.
zAfter adjustment for fat mass.
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